MedTrace Logo

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

NCT03652857 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-17

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer

Conditions

  • Advanced Non Small Cell Lung Cancer

Interventions

DRUG

Apatinib Combined With Vinorelbine

Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months

Sponsors & Collaborators

  • Yongchang Zhang

    lead OTHER

Principal Investigators

  • Nong Yang, MD · Hunan Province Tumor Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-11-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652857 on ClinicalTrials.gov